Esophageal Cancer
Conditions
Keywords
peptide vaccine, URLC10
Brief summary
The purpose of this study it to evaluate the safety and immune response of peptides (URLC10) emulsified with Montanide ISA51 in treating patients with unresectable, advanced or recurrent esophageal cancer.
Detailed description
URLC10 have been identified as cancer specific molecules especially in non small cell lung cancer using genome-wide expression profile analysis by cDNA microarray technique. In a prior study, it has been shown that URLC10 are upregulated in human esophageal tumors. The investigators identified that peptides derived from these proteins significantly induce the effective tumor specific CTL response in vitro. According to these findings, in this trial, we evaluate the safety, immunological and clinical response of URLC10 peptide. Patients will be vaccinated once in one week to the eighth vaccine and will be vaccinated once in two weeks from the ninth vaccine. On each vaccination day, the URLC10 peptide (1mg) mixed with Montanide ISA 51 will be administered by endodermic injection
Interventions
BIOLOGICALURLC10
Biological: URC10 Patients will be vaccinated once in one week to the eighth vaccine and will be vaccinated once in two weeks from the ninth vaccine. On each vaccination day, the URLC10 peptide (1mg) mixed with Montanide ISA 51 will be administered by endodermic injection.
Sponsors
Human Genome Center, Institute of Medical Science, University of Tokyo
Kinki University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Patients must have Advanced or recurrent esophageal cancer, and treatment has failed, or in the situation where effective therapy is not available, or has been refused due to severe adverse effects of chemotherapy 2. WHO performance status of 0 to 2 3. Age ≥ 20 years, ≤80 years 4. The patient does not need to have a measurable disease, but must have a disease that an effect judgment is possible 5. Passing from previous treatment more than two weeks. Passing from radiation therapy more than four weeks. 6. Expected survival of at least 3 months 7. WBC≥ 1,500/mm³ WBC≤ 15,000/mm³ Platelet count ≥ 50,000/mm³ Total bilirubin ≤ 3 x the institutional normal upper limits AST, ALT ≤ 3 x the institutional normal upper limits Creatinine ≤ 3 x the institutional normal upper limits 8. Patients must be HLA-A2402 9. Able and willing to give valid written informed consent
Exclusion criteria
1. Pregnancy, Promise of the pregnancy, Hope of the pregnancy, Breastfeeding 2. Serious infections requiring antibiotics 3. Concurrent treatment with steroids or immunosuppressing agent 4. Disease to the central nervous system 5. Decision of unsuitableness by principal investigator or physician-in-charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety(Phase I:toxicities as assessed by NCI CTCAE version3) | 28 days after beginning protocol |
Secondary
| Measure | Time frame |
|---|---|
| efficacy(Feasibility as evaluated by RECIST) | 28 days after beginning protocol |
| evaluate immunological responses | 28 days after beginning protocol |
Countries
Japan
Outcome results
None listed